A

Advanced Research for Health Improvement, LLC | Naples, FL

Research site
(Unclaimed)
Location
1168 Goodlette Frank Road North, Suite 201, Naples, Florida, United States of America

Site insights

Top conditions

Top treatments

Ozanimod
Linaclotide
Olpasiran
Pelacarsen
Milvexian
GB0139
TQJ230
Olodaterol
Tiotropium

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 13 total trials

A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease (COORDINATE)

COORDINATE-Diabetes is a cluster-randomized clinical trial to test the effectiveness of an innovative, clinic-level educational intervention to impro...

Active, not recruiting
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Other: Intense Education Intervention

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compar...

Enrolling
Aortic Stenosis
Drug: Matching placebo
Drug: Pelacarsen (TQJ230) 80mg

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod
Other: Placebo

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod

The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pedi...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Linaclotide 145 μg (IBS-C Participants)
Drug: Linaclotide 72 μg (FC Participants)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

Trial sponsors

Amgen logo
Celgene logo
AbbVie logo
Boehringer Ingelheim logo
Duke University logo
G
J
Lilly logo
L
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems